2024
Vaccination to Prevent Lyme Disease: A Movement Towards Anti-Tick Approaches
Johnson E, Hart T, Fikrig E. Vaccination to Prevent Lyme Disease: A Movement Towards Anti-Tick Approaches. The Journal Of Infectious Diseases 2024, 230: s82-s86. PMID: 39140718, PMCID: PMC11322886, DOI: 10.1093/infdis/jiae202.Peer-Reviewed Original ResearchConceptsTransmission of tick-borne pathogensTick-borne pathogensIxodes spp ticksInhibited tick feedingTick feedingDisease vaccineTick vectorWildlife reservoirsOuter surface protein ALyme disease vaccineLyme diseaseTicksBorrelia burgdorferiLyme disease casesPreventing Lyme diseasePathogensFood and Drug AdministrationSurface protein AOspA-based vaccinesVaccineFeedingLymeProtein AFoodPrevent transmission
2023
Development of an mRNA-lipid nanoparticle vaccine against Lyme disease
Pine M, Arora G, Hart T, Bettini E, Gaudette B, Muramatsu H, Tombácz I, Kambayashi T, Tam Y, Brisson D, Allman D, Locci M, Weissman D, Fikrig E, Pardi N. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease. Molecular Therapy 2023, 31: 2702-2714. PMID: 37533256, PMCID: PMC10492027, DOI: 10.1016/j.ymthe.2023.07.022.Peer-Reviewed Original ResearchConceptsLyme diseaseImmune responseCell-mediated immune responsesLyme disease vaccinePotent immune responsesProtein subunit vaccinesSARS-CoV-2Surface protein AVector-borne infectious diseasesMRNA-LNP vaccineOuter surface protein ASingle immunizationProtective efficacyMRNA vaccinesClinical vaccinesDisease vaccineNanoparticle vaccineSubunit vaccineVaccine developmentVaccineBacterial infectionsMRNA-LNPInfectious diseasesDiseaseMRNA platform
2021
Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States
Hook SA, Hansen AP, Niesobecki SA, Meek JI, Bjork JKH, Kough EM, Peterson MS, Schiffman EK, Rutz HJ, Rowe AJ, White JL, Peel JL, Biggerstaff BJ, Hinckley AF. Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States. Vaccine 2021, 40: 298-305. PMID: 34895785, PMCID: PMC11705932, DOI: 10.1016/j.vaccine.2021.11.065.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineSurvey-weighted descriptive statisticsMultivariable multinomial logistic regression modelsCross-sectional studyLyme disease incidenceHigh incidence areaCross-sectional surveyLogistic regression modelsSafety concernsMultinomial logistic regression modelsVaccine uptakeAdults 45Vaccine parametersVaccine candidatesVaccine attitudesPrevention optionsHealthcare providersWeb-based surveyVaccineSociodemographic characteristicsIncidence areaLyme diseaseDisease incidenceIncidence
2019
Knowledge, attitudes, and behaviors regarding tick-borne disease prevention in endemic areas
Niesobecki S, Hansen A, Rutz H, Mehta S, Feldman K, Meek J, Niccolai L, Hook S, Hinckley A. Knowledge, attitudes, and behaviors regarding tick-borne disease prevention in endemic areas. Ticks And Tick-borne Diseases 2019, 10: 101264. PMID: 31431351, PMCID: PMC10948045, DOI: 10.1016/j.ttbdis.2019.07.008.Peer-Reviewed Original ResearchConceptsEndemic areasPrevalence of LDPrevention behaviorsShowering/bathingTick checksDisease preventionPerceived PrevalenceLyme disease vaccineLD endemic areasInsect repellentSelf-rated knowledgeUnadjusted analysesOdds ratioMultivariable modelFemale genderLD vaccineDisease vaccinePrevention optionsLocal prevalencePreventive behaviorsSociodemographic characteristicsPrevalenceMajority of respondentsOnly factorTick control
2003
An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine
Schoen RT, Deshefy-Longhi T, Van-Hoecke C, Buscarino C, Fikrig E. An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine. Clinical Therapeutics 2003, 25: 210-224. PMID: 12637121, DOI: 10.1016/s0149-2918(03)90027-0.Peer-Reviewed Original ResearchConceptsLyme disease vaccineFirst booster doseSecond booster doseBooster doseAdverse eventsBooster dosesPrimary seriesMonth 24Disease vaccineClinical trialsEfficacy trialsImmune responseIncidence of AEsPattern of AEsLyme diseaseMost adverse eventsGeometric mean titersTotal IgG antibodiesProportion of subjectsPositive test resultsSeroprotective levelsBooster vaccinationMonth 36Third vaccinationDiary cards
2002
The Lyme Disease Vaccine Takes Its Toll
Thomas V, Fikrig E. The Lyme Disease Vaccine Takes Its Toll. Vector-Borne And Zoonotic Diseases 2002, 2: 217-222. PMID: 12804162, DOI: 10.1089/153036602321653798.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, BacterialAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferiHumansLipoproteinsLyme DiseaseLyme Disease VaccinesMembrane GlycoproteinsMiceMice, KnockoutReceptors, Cell SurfaceToll-Like Receptor 1Toll-Like Receptor 2Toll-Like ReceptorsConceptsTLR2-deficient miceToll-like receptorsPathogen-associated molecular patternsOspA antibodiesSpecific Toll-like receptorsBorrelia burgdorferi outer surface proteinDetectable humoral responseMolecular patternsProtective immune responseLyme disease vaccineDistinct pathogen-associated molecular patternsVaccine recipientsHumoral responseOspA vaccineCell surface expressionOspA vaccinationImmune responseDisease vaccineInnate responseTLR2Protective responseOuter surface proteinsTLR1Lyme diseaseDevelopment of responsesHyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice
Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT, Medzhitov R, Fikrig E, Flavell RA. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nature Medicine 2002, 8: 878-884. PMID: 12091878, DOI: 10.1038/nm732.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, BacterialAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferiCell SeparationCells, CulturedDrosophila ProteinsHumansInterleukinsLipoproteinsLyme Disease VaccinesMacrophagesMembrane GlycoproteinsMiceMice, KnockoutReceptors, Cell SurfaceSignal TransductionToll-Like Receptor 1Toll-Like Receptor 2Toll-Like ReceptorsConceptsToll-like receptor 1Less tumor necrosis factorTLR2-deficient miceLow antibody titersLyme disease vaccineTumor necrosis factorLow cell surface expressionOuter surface lipoproteinsVaccine recipientsAntibody titersInterleukin-6Cell surface expressionNecrosis factorOspA vaccinationDisease vaccineLow respondersInnate responseTLR2Low titersReceptor 1Substantial titersVaccinationMiceTLR1Borrelia burgdorferi
2001
Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial
Sikand V, Halsey N, Krause P, Sood S, Geller R, Van Hoecke C, Buscarino C, Parenti D. Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial. 2001, 108: 123-128. PMID: 11433064, DOI: 10.1542/peds.108.1.123.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntigens, SurfaceArthralgiaBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferi GroupChildChild, PreschoolEdemaErythemaExanthemaFatigueFemaleFeverHeadacheHumansImmunoglobulin GIncidenceInjectionsLipoproteinsLyme DiseaseLyme Disease VaccinesMalePainSeverity of Illness IndexTime FactorsUnited StatesConceptsLocal injection site reactionsInjection site reactionsYears of ageMonth 13LD vaccineVaccine recipientsSite reactionsHealthy childrenEfficacy studiesChildren 4Placebo-controlled clinical trialUnsolicited adverse eventsFlu-like symptomsLyme disease vaccineHigher immune responseLyme endemic areasOuter surface proteinsAdolescents 15 yearsIgG GMTPlacebo recipientsReactogenicity dataAdverse eventsControlled TrialsMonth 6Immunogenicity data
2000
The Lyme disease vaccine: conception, development, and implementation.
Thanassi W, Schoen R. The Lyme disease vaccine: conception, development, and implementation. Annals Of Internal Medicine 2000, 132: 661-8. PMID: 10766685, DOI: 10.7326/0003-4819-132-8-200004180-00009.Peer-Reviewed Original ResearchSafety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months
Schoen R, Sikand V, Caldwell M, Van Hoecke C, Gillet M, Buscarino C, Parenti D. Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clinical Therapeutics 2000, 22: 315-325. PMID: 10963286, DOI: 10.1016/s0149-2918(00)80035-1.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineThird doseRecombinant outer surface protein A (OspA) vaccineOuter surface protein A (OspA) vaccineRecombinant outer surface proteinGeometric mean antibody titersVaccine 1 monthMost adverse eventsDoses of vaccineMean antibody titersLyme disease endemic areaEnzyme-linked immunosorbentDisease-endemic areasA vaccineAdverse eventsRandomized studyVaccination scheduleImmunogenicity profileSafety profileAntibody titersMonths 0Month 2Clinical trialsEfficacy trials
1997
Borrelia burgdorferi genes selectively expressed in ticks and mammals
de Silva AM, Fikrig E. Borrelia burgdorferi genes selectively expressed in ticks and mammals. Trends In Parasitology 1997, 13: 267-270. PMID: 15275064, DOI: 10.1016/s0169-4758(97)01074-0.Peer-Reviewed Original ResearchLyme disease vaccineTick-borne infectionsDisease vaccineHuman trialsSpirochete Borrelia burgdorferiDifferent surface proteinsLyme diseaseBorrelia burgdorferiLyme disease bacteriumBorrelia burgdorferi genesDisease bacteriumSurface proteinsRecent studiesDifferential gene expressionLife styleGene expressionVaccineInfectionDiseaseBorrelia burgdorferi enzyme-linked immunosorbent assay for discrimination of OspA vaccination from spirochete infection
Zhang YQ, Mathiesen D, Kolbert CP, Anderson J, Schoen RT, Fikrig E, Persing DH. Borrelia burgdorferi enzyme-linked immunosorbent assay for discrimination of OspA vaccination from spirochete infection. Journal Of Clinical Microbiology 1997, 35: 233-238. PMID: 8968914, PMCID: PMC229545, DOI: 10.1128/jcm.35.1.233-238.1997.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayVaccine failureFalse positivityAntigen preparationsExperimental animalsNatural infectionLyme disease vaccineB. burgdorferiExperimental animal modelsNegative enzyme-linked immunosorbent assayEnzyme-linked immunosorbentWhole-cell sonicateSurface protein AVaccinated subjectsLyme disease casesOuter surface protein AVaccinated personsFalse-positive resultsVaccine trialsOspA vaccinationSpirochete infectionDisease vaccineAnimal modelsHuman Lyme disease casesNegative isolates
1996
Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine
Ma J, Hine P, Clough E, Fish D, Coughlin R, Beltz G, Shew M. Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine. Vaccine 1996, 14: 1366-1374. PMID: 9004447, DOI: 10.1016/s0264-410x(96)00045-x.Peer-Reviewed Original ResearchConceptsCanine Lyme disease vaccineLyme disease vaccineDisease vaccineGeometric mean antibody titersInjection site swellingMean antibody titersTypical clinical signsMonths postchallengeVaccination timeSecond vaccinationBorrelial antigensSpirochetal antigensAntibody titersProtective efficacyControl beaglesAdverse reactionsVaccinated dogsClinical signsImmunological memoryLocal reactionsAntibody productionNormal beaglesVaccinatesLyme diseaseOsp ABorrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine.
de Silva AM, Telford SR, Brunet LR, Barthold SW, Fikrig E. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. Journal Of Experimental Medicine 1996, 183: 271-275. PMID: 8551231, PMCID: PMC2192397, DOI: 10.1084/jem.183.1.271.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, BacterialAntigens, BacterialAntigens, SurfaceArachnid VectorsBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferi GroupDigestive SystemFluorescent Antibody TechniqueImmunotherapy, AdoptiveIxodesLipoproteinsLyme DiseaseMiceMice, Inbred C3HSalivary GlandsConceptsOspA antibodiesTick attachmentUnfed nymphal ticksLyme disease vaccineB. burgdorferi infectionBlood mealMechanism of protectionTick blood mealSpirochete infectionBurgdorferi infectionDisease vaccineGland invasionExpression of OspAOuter surface proteinsSpirochetal agentLyme diseaseMiceSalivary gland invasionAntibodiesSalivary glandsBorrelia burgdorferiIxodes ticksOspA expressionTick gutVaccine
1995
Progress Towards a Vaccine for Lyme Disease
Telford S, Fikrig E. Progress Towards a Vaccine for Lyme Disease. BioDrugs 1995, 4: 49-60. DOI: 10.1007/bf03259070.Peer-Reviewed Original ResearchLyme diseaseLyme disease vaccineSurface protein AOuter surface protein AProtective immunityPrototype vaccineCareful surveillanceClinical trialsChronic natureDisease vaccineSuch vaccinesMouse modelVaccinated hostAdvanced stageVaccineDiseaseInfectious ticksInfectionAntibodiesProtein AYearsMiceImmunityTrials
1994
Partial destruction of Borrelia burgdorferi within ticks that engorged on OspE- or OspF-immunized mice
Nguyen TP, Lam TT, Barthold SW, Telford SR, Flavell RA, Fikrig E. Partial destruction of Borrelia burgdorferi within ticks that engorged on OspE- or OspF-immunized mice. Infection And Immunity 1994, 62: 2079-2084. PMID: 8168973, PMCID: PMC186469, DOI: 10.1128/iai.62.5.2079-2084.1994.Peer-Reviewed Original ResearchConceptsEarly-stage disease patientsMajority of patientsLate-stage diseaseSerum of miceLyme disease vaccineB. burgdorferiB. burgdorferi organismsExamination of seraNumber of spirochetesOuter surface protein ESyringe challengeDisease patientsImmune responseDisease vaccinePatientsHigh titersLyme diseaseMiceAntibodiesDiseaseSerumBurgdorferiBorreliaDaysProtein EA Recombinant OspA and OspB Based Lyme Disease Vaccine
Fikrig E, Kantor F, Barthold S, Flavell R. A Recombinant OspA and OspB Based Lyme Disease Vaccine. NATO Science Series A: 1994, 25-31. DOI: 10.1007/978-1-4615-2415-1_5.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply